Day: February 27, 2025

– Received FDA Fast Track Designation for DYNE-101 in DM1 – – Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval – – Full Enrollment of Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD Planned for Q1 2025 to Support Submission for U.S. Accelerated Approval – WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. “Our most recent clinical data for DYNE-101 from the ACHIEVE trial in...

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE) Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027 Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year end Actively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25 Ended 2024 with approximately $862 million in cash, cash equivalents and marketable securitiesCAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE)...

Net revenue in Q4 2024 increased by 27% year-over-year to $30.3 million; Net revenue in FY 2024 increased by 35% year-over-year to $117.6 million Spinach® Ends 2024 as the Number One Cannabis Brand in Canada1 PEACE NATURALS® Ends 2024 as the Number One Cannabis Brand in Israel 2 Industry leading balance sheet with $859 million in cash and cash equivalents TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2024 fourth quarter and full-year business results. “We set ambitious goals to deliver robust growth, improve margins, and achieve operational excellence. Today, I am proud to say that Cronos has not only met but exceeded these objectives, as evidenced by our strong 2024 results. Our unwavering commitment to innovation, quality, and disciplined...

Fiscal Year 2024 Net Revenue of $606.3 million, up 28.5% versus Fiscal Year 2023FY 2025 Outlook of $740 million in Net Revenue and $100 million in Adjusted EBITDAOn Track to Reach $1 Billion Net Revenue Target in 2027 AUSTIN, Texas, Feb. 27, 2025 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its fourth quarter and fiscal year ended December 29, 2024. Financial highlights for the fourth quarter ended December 29, 2024 (13 weeks), compared to the fourth quarter ended December 31, 2023 (14 weeks), include:Net Revenue increased 22.2% to $166.0 million on a reported basis, compared to $135.8 million, and increased 30% on a like-for-like basis when accounting for one fewer week in the fourth quarter of 2024 (13...

SANTA MONICA, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) has released its Fourth Quarter 2024 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at investing.macerich.com. As previously announced, management will hold a conference call at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) today, Thursday, February 27, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the webcast registration link below or in the Investors Section of the company’s website at investing.macerich.com. Dial-In...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2024. “Vertex’s 2024 financial results demonstrated the power of our business and financial model, which is built to deliver consistent and durable mid-to-high teens revenue growth with strong earnings leverage and cash flow,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “We believe the secular tailwinds that enable our performance will accelerate in the coming years as indirect taxes continue to grow in complexity, and enterprise technology continues to evolve and move to the cloud.” Fourth Quarter 2024 Financial ResultsTotal...

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ ~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~ ~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy (mTLE); Implementing protocol changes to expand study inclusion criteria ~ ~ Completed enrollment of the first cohorts in the Phase I/II studies of AMT-191 in Fabry disease and AMT-162 in SOD1-ALS; Received favorable recommendations from the respective Independent Data Monitoring Committees (IDMC) to proceed with dosing the second cohorts ~ ~ Cash and cash equivalents of approximately $367.5 million as of December 31, 2024,...

Reports another quarter of accelerated growth and profitability, achieved Q4 guidance on Ex TAC gross profit and Adjusted EBITDA, and generated strong cash flow Closed acquisition of Teads in February 2025; Combined company operating under the name Teads NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) — Outbrain Inc. (Nasdaq: OB), which is operating under the new Teads brand, announced today financial results for the quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Key Financial Metrics:  Three Months EndedDecember 31,   Twelve Months EndedDecember 31,(in millions USD)   2024       2023     % Change     2024       2023     % ChangeRevenue $ 234.6     $ 248.2       (5 )%   $ 889.9     $ 935.8       (5 )%Gross profit   56.1       53.2       5  %     192.1       184.8       4  %Net (loss) income   (0.2 )     4.1       (104 )%     (0.7 )     10.2       (107 )%Net...

Completed Acquisition of Sterling; Issues Full Year 2025 Guidance Full Year 2024 Highlights1Revenues of $860.2 million Net Loss of $(110.3) million, a net loss margin of (12.8)%, includes $130.5 million of expenses incurred related to the acquisition of Sterling Check Corp. (“Sterling”) Adjusted Net Income of $123.7 million Adjusted EBITDA of $249.3 million; Adjusted EBITDA Margin of 29.0% GAAP Diluted Net Loss Per Share of $(0.74), includes $0.66 per share of expenses incurred related to the Sterling acquisition Adjusted Diluted Earnings Per Share of $0.82 Cash Flows from Operations of $28.2 million; Adjusted Operating Cash Flows of $164.5 million, after adjusting for $136.3 million of cash costs directly associated with the Sterling acquisition Closed the Sterling acquisition on October 31, 2024, which was first announced on February...